Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis

Rheumatology International

Volumn 30, Issue 5, 2010, Pages 709-712

  Henes, Joerg Christoph ^a   Schedel, Joerg ^a   Kanz, Lothar ^a   Koetter, Ina ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Leflunomide; Rheumatoid arthritis; Rituximab

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; LIVER ENZYME; MEPREDNISONE; METHOTREXATE; RITUXIMAB;

ADULT; AGED; ARTICLE; CASE STUDY; CLINICAL ARTICLE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; LUNG FIBROSIS; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; RETREATMENT; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SIDE EFFECT; TREATMENT RESPONSE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951023306     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1302-z     Document Type: Article

References (10)

1. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, DANCER Study Group et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum 54(5):1390-1400
2. Edwards JC, Szczepanski L, Szczecinski J, Filipowicz- Sosnowska A, Emery P, Close DR et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572-2581 (Pubitemid 38758544)
3. Kalden JR, Schattenkirchner M, Sörensen H, Emery P, Deighton C, Rozman B et al (2003) The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum 48(6):1513-1520
4. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315-324
5. van der Heijde DM, van't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA et al (1990) Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 49:916-920
6. van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41(10):1845-1850
7. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, REFLEX Trial Group et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo- controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54(9):2793-2806
8. Finckh A, Dehler S, Gabay C (2009) The effectiveness of leflunomide as co-therapy of TNF inhibitors in rheumatoid arthritis. A population based study. Ann Rheum Dis 68:33-39
9. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J et al (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56(12):3896-3908
10. Owczarczyk K, Hellmann M, Fliedner G, Röhrs T, Maizus K, Passon D et al (2008) Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Ann Rheum Dis 67(11):1648-1649